THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, AND THE INFORMATION
CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION
OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN,
INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA,
JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA, NOR IS IT TO BE
TRANSMITTED OR DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT
OR CITIZEN OF ANY SUCH COUNTRIES OR OF ANY OTHER JURISDICTION IN
WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE
LOCAL SECURITIES LAWS OR REGULATIONS. PLEASE SEE THE IMPORTANT
NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, DOES NOT ITSELF
CONSTITUTE AN OFFER TO BUY, ACQUIRE OR SUBSCRIBE FOR (OR THE
SOLICITATION OF AN OFFER TO BUY, ACQUIRE OR SUBSCRIBE FOR) ORDINARY
SHARES TO ANY PERSON. IN PARTICULAR, THIS ANNOUNCEMENT,
INCLUDING THE APPENDIX, DOES NOT CONSTITUTE OR CONTAIN ANY
INVITATION, SOLICITATION OR OFFER TO ANY PERSON WITH A REGISTERED
ADDRESS IN, LOCATED IN, OR WHO IS A RESIDENT OF, THE UNITED STATES,
AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA
OR ANY OTHER JURISDICTION IN WHICH SUCH INVITATION, SOLICITATION OR
OFFER WOULD BE UNLAWFUL OR CONTRAVENE ANY REGISTRATION OR
QUALIFICATION REQUIREMENTS UNDER THE SECURITIES LAWS OF ANY SUCH
JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK
DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018,
AS AMENDED ("MAR").
25 July
2024
Pantheon Resources
plc
Proposed Placing and
Subscription to raise a minimum of $18.5 million
Pantheon Resources plc
("Pantheon" or the
"Company"), the oil and gas
company with a 100% working interest in the Kodiak and Ahpun
projects located in close proximity to pipeline and transportation
infrastructure on Alaska's North Slope, is pleased to announce that
it intends to raise a minimum of $18.5 million by way of a placing
and conditional subscriptions (together the "Fundraise") of new Ordinary Shares at a
price of 17 pence per share (the "Issue Price").
The purpose of the Fundraise is
principally to fund the drilling of the Megrez-1 well located in
the Ahpun Eastern Topset area, and, together with existing cash
resources, to cover lease rentals,
development of the Company's asset portfolio and provide general
working capital for the Group.
Institutional investors will
participate by way of a placing of new Ordinary Shares
(the "Placing Shares") conducted through an
accelerated bookbuild (the "Bookbuild") which will be launched
immediately following this Announcement (the "Placing"). Canaccord Genuity
Limited ("Canaccord") and
Zeus Capital Limited ("Zeus
Capital") are acting as joint bookrunners in connection with
the Placing (the "Joint
Bookrunners" and each a "Bookrunner"). The Placing is
not being underwritten.
Certain investors will also be
subscribing for new Ordinary Shares (the "Subscription Shares") at the Issue
Price directly with the Company (the "Subscription"). The Subscription is
conditional on completion of the Placing.
In addition to the Placing and the
Subscription, retail investors will be given an opportunity to
participate by subscribing for new Ordinary Shares (the
"Retail Offer Shares") at the Issue Price (the
"Retail Offer") on the
PrimaryBid platform. A separate announcement will be made shortly
regarding the Retail Offer and its terms. The Placing and
Subscription are not conditional upon the Retail Offer. The Retail
Offer will close on completion of the Bookbuild process.
The holder of the Convertible Bond
has indicated its intention to participate in the Placing for $4
million, subject to a minimum of $18.5 million (inclusive of this
amount) being raised in the Fundraise. Additionally, and subject to
the same condition, the Company has agreed to prepay at the time of
the Placing the final two principal amortisation payments under the
Convertible Bond of $2.45 million each, originally falling due in
September and December 2026, by way of issuing 22,380,254 new
Ordinary Shares at the Issue Price (at a £:$ rate of
1.2879).
The Company considers it important
to be able to take advantage of investor demand should investors
wish to participate in the Fundraise in excess of $18.5 million. In
such an event, therefore, the Company will likely increase the
amount proposed to be raised pursuant to the Fundraise. Any
additional proceeds above the minimum of $18.5 million,
including from the Retail Offer,
will be applied towards extended flow testing at
Megrez-1 (in a success
case), further development of the Company's
asset portfolio and general corporate purposes.
The Placing is subject to the terms
and conditions set out in the Appendix to this Announcement (which
forms part of this Announcement).
The final number of New Ordinary
Shares to be issued will be announced immediately following the
closing of the Bookbuild process and Retail Offer. The New Ordinary
Shares, when issued, will be credited as fully paid and will rank
pari passu in all respects
with the Existing Ordinary Shares, including the right to receive
all dividends and other distributions declared, made or paid on or
in respect of such shares after the date of issue.
Application will be made for
Admission of the New Ordinary Shares and it is expected that
Admission will take place at or around 8.00 ‎a.m. (London time)
on 2 August 2024 (or such later time and/or date as may be agreed between the
‎Company and the Joint Bookrunners, being not later than 8.00 ‎a.m.
(London time) on 9 August
2024). The Fundraise is conditional upon,
inter alia, Admission ‎becoming effective. The Placing is also
conditional upon the Company having received payment from the
Subscription in respect of the Subscription Shares and the Placing
Agreement not otherwise being ‎terminated in accordance with its
terms.
The Announcement should be read in
its entirety. In particular, you should read and understand the
information provided in the "IMPORTANT NOTICES" section and the
detailed terms and conditions described in the Appendix.
David Hobbs, Executive Chairman, said:
"We have seen a year of significant progress,
which included receipt of Independent Expert Reports totalling 1.57
billion bbls of Contingent Recoverable Resources of ANS Crude,
execution of a Gas Sales Precedent Agreement with AGDC (Alaska
Gasline Development Corporation) that may support substantial
funding of field development costs, the strengthening of
governance, and alignment with shareholders. Success at the
Megrez-1 well would prove up the eastern portion of our Ahpun
acreage.
The location of these high-quality prospective resources
immediately adjacent to the pipeline and highway are a potential
gamechanger. Their materially improved reservoir characteristics
when compared to the existing topsets in the western portion (and,
to an even greater extent, the Alkaid horizon) of Ahpun will
provide vital information in our development modelling for the
overall Ahpun project. This is especially important in aligning the
timetable for achieving FID for Ahpun with the proposed gas supply
initiatives from AGDC and the State of Alaska."
Jay
Cheatham, CEO of Pantheon Resources, said: "Management estimates have
the Megrez-1 well targeting c.600 mmbls of P50 prospective resource
in Ahpun's eastern topsets, where we expect excellent reservoir
parameters analogous to the proven productive reservoirs now being
developed at Horseshoe/Pikka and Willow, which is the source of
expected new production growth on the Alaska North Slope.
Company-modelled individual well economics in the eastern topsets,
if successful, have the potential for very attractive NPV10s
exceeding $30/bbl (at $80 oil). Our technical team, which has a
100% drilling success rate encountering oil pay when based on 3D
seismic AVO, has assessed the probability of discovering oil at
Megrez-1 at 69%, based on data acquired over a decade especially
from nearby discoveries in Pantheon's acreage and seismic
anomalies. The size, location and potential economic impact of a
success case at Megrez-1 make it amongst Pantheon's most impactful
drilling ventures with the potential to transform the Greater Ahpun
development project and the entire company.
The measure of our confidence in the success of this low risk
well on the eastern extension of Ahpun and the wider Pantheon asset
portfolio is that all of our Board and certain key advisers are
participating for a combined amount of c.$1.0 million in the
Fundraise."
Further information:
Pantheon Resources plc
|
+44 20 7484 5361
|
David Hobbs, Executive
Chairman
Jay Cheatham, CEO
Justin Hondris, Director, Finance and
Corporate Development
|
|
|
|
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser, Sole Broker
and Joint Bookrunner)
|
|
Henry Fitzgerald-O'Connor
James Asensio
Ana Ercegovic
|
+44 20 7523 8000
|
|
|
|
|
Zeus
Capital (Joint Bookrunner)
|
+44 20 3829
5000
|
Harry Ansell
|
|
Katy Mitchell
|
|
|
|
BlytheRay (Corporate Communications)
|
|
Tim Blythe
Megan Ray
Matthew Bowld
|
+44 20 7138 3204
|
Background to the Fundraise
Pantheon has made significant
progress during the last 12 months on a number of
initiatives:
(i) Receipt of
Independent Expert Report by Netherland Sewell & Associates in
April 2024, certifying 2C Contingent Resources of 1.2 billion
barrels of marketable liquids.
(ii) Receipt of
Independent Expert Report by Lee Keeling & Associates (LKA) in
April 2024, certifying 2C Contingent Resources of 79 million
barrels of marketable liquids and an estimated NPV10 at $80 oil of
$200 - $530 million(1).
(iii) Receipt of Independent
Expert Report by Cawley Gillespie & Associates (CGA) in June
2024, certifying 2C Contingent Resources of 282 million barrels of
marketable liquids and an estimated NPV10 at $80 oil of $1.74
billion(1).
(iv) Execution of Gas Sales
Precedent Agreement with AGDC which provides potential for a long
term supply contract, which management estimates could provide
funding capacity through potential debt backed by Take or Pay
Contract, for up to US$250 million(2).
(v) Pantheon was the
successful bidder for an additional 66,240 acres of leases at the
State of Alaska's December 2023 lease sale. These new leases,
immediately to the east of Ahpun and updip to the west and
north-west of Kodiak, include some of the highest quality areas of
the two fields, at the shallowest depths.
(vi) Successful testing of the shallower topsets in the Alkaid-2
wellbore, which exceeded our expectations and validated the
effectiveness of the revised frac design, achieving a c.2.5x
improvement over that achieved at the deeper Alkaid
reservoir.
(1) LKA NPV10 calculations are exclusive of federal and state
income taxes; CGA NPV10 calculations are after deduction of state
production taxes and ad valorem taxes but before consideration of
federal income taxes.
(2) Based on 50% of Real NPV10 of post-tax gas revenues with
no capital offsets and subject to final gas sales agreement
execution.
Following the achievement of these
milestones, Pantheon is focused on its stated goals of advancing
both the Ahpun and Kodiak projects towards FID, and ultimately
development of these projects. Fundamental to this goal is to
provide sufficient additional data to both support, and potentially
accelerate these objectives. Megrez-1 is located on the new Ahpun
East Topset acreage where the reservoir section to be targeted is
younger and shallower, with superior reservoir characteristics than
in any of Pantheon's wells to date. Pantheon believes this to be a
conventional reservoir with reservoir porosities of 20 - 25% and
permeabilities of 5 - 35 millidarcies containing high quality light
oil consistent with that encountered in Pantheon's other wells. A
success at Megrez-1 is expected to accelerate development horizons
and will greatly enhance the economics of the full Ahpun
development. A successful fundraising at this time allows the
possibility to obtain the requisite licences, equipment and
services to spud the Megrez-1 well as early as Q4 2024.
Following further analysis
undertaken subsequent to receipt of the various Independent Expert
Reports, the Company has updated its well modelling estimates which
are presented in the table below.
Conceptual per well NPV10 sensitivity
analysis
Company estimates - for illustrative purposes
only
EUR per
well
|
Megrez-1
East Ahpun Top
Set
9.57 MMBBL
|
Kodiak Theta
West
3.68 MMBBL
|
West Ahpun Top
Set
3.48 MMBBL
|
Pricing
|
NPV10
($mln)
|
NPV10
per
bbl.($)
|
NPV10
($mln)
|
NPV10
per
bbl.($)
|
NPV10
($mln)
|
NPV10
per
bbl.($)
|
$60
|
$202.3
|
$21.1
|
$54.3
|
$14.8
|
$30.0
|
$8.6
|
$70
|
$249.3
|
$26.0
|
$71.7
|
$19.5
|
$40.7
|
$11.7
|
$80
|
$296.3
|
$30.9
|
$89.0
|
$24.2
|
$51.5
|
$14.8
|
$90
|
$343.3
|
$35.8
|
$106.4
|
$28.9
|
$62.2
|
$17.9
|
Principal assumptions and management estimates (Outturn may
differ from assumptions)
• Prices have been discounted by 10% from ANS
for quality bank adjustment
• No revenues for natural gas
• Combination of TAPS tariff and shipping to US
West Coast estimated at $10.00 bbl
• Production well cost of $24.5 million ($22.6
million for Ahpun East) includes allocation of:
• 1 injection well for every 3 production
wells
• Well pads and production facilities estimated
at $2.5 million per well (based on estimated $50 million for 20
well pad)
• Royalty rates modelled at between 17.5 -
18%
• After severance/production
taxes
• Before Federal Taxes
• These estimates are based upon estimates at
the current time and actual outcomes may differ from those
presented, so must be considered as for illustrative purposes
only.
Summary - Use of Proceeds
The gross minimum proceeds of the
Fundraise of $18.5 million are expected to be used as
follows:
Drilling of Megrez-1 well
|
$15.9m
|
Other
|
$2.6m
|
Minimum fundraise
|
$18.5m
|
Drilling of the Megrez-1 well is
subject to ordinary course permitting, targeting an Autumn/Winter
2024/25 spud. The Megrez-1 Dry Hole Cost includes logging and fluid
sample gathering.
$2.6 million, together with existing
cash resources, will be allocated to working capital which includes
lease rentals, development of the Company's asset portfolio
(including technical work), transaction costs and general working
capital.
Based on the use of funds set out
above, the Company expects that this amount will provide sufficient
working capital for the Group for up to the next 12 months. In
forming this view, it is assumed that all quarterly amortisation
and interest payments due on the Company's Convertible Bond will
continue to be paid in shares.
The minimum fundraise prioritises
drilling activities over other Company initiatives and does not
include funding for a U.S. IPO, for extended flow testing at
Megrez-1 (in a success case) or for advanced engineering on the
proposed hot-tap at this time.
Any additional proceeds above the
minimum of $18.5 million, including from the Retail Offer, will be
applied towards extended flow testing at Megrez-1 (in a success
case), further development of the Company's asset portfolio
and general corporate
purposes.
Directors, management and advisers
participation
All of the Directors, as well as
certain management and advisers, have indicated that they
intend to participate in the Subscription for an aggregate amount
of approximately $1.0 million. The ultimate allocation to the
Directors is at the absolute discretion of Canaccord, Zeus Capital
and the Company.
Convertible Bond
A summary of the principal terms of
the Convertible Bond have been set out previously in an
announcement dated 7 December 2021. The holder of the Convertible
Bond has indicated its intention to participate in the Placing for
$4 million, subject to a minimum of $18.5 million (inclusive of
this amount) being raised in the Fundraise. Additionally, and
subject to the same condition, the Company has agreed to prepay at
the time of the Placing the final two principal amortisation
payments under the Convertible Bond of $2.45 million each,
originally falling due in September and December 2026, by way of
issuing 22,380,254 new Ordinary Shares at the Issue Price (at a £:$
rate of 1.2879 (the "Bond
Prepayment Shares"), subject to, and on Admission, after
which the outstanding principal owing on the Convertible Bond will
reduce to $19.6 million (the "Bond
Prepayment"). The Bond Prepayment Shares and the Bond
Prepayment do not form part of the Fundraise. As a consequence of
the Fundraise, and pursuant to the anti-dilution provisions of the
Convertible Bond, the Company expects that there will be a minor
adjustment to the conversion price of the Convertible Bond. There
are no adjustments to how the amortisation and interest payments
will be calculated if to be satisfied by shares.
Share Option Plan
The Company intends to implement a
revised long-term incentive plan (LTIP), replacing the old reserves
based and option plans, that include both options and restricted
stock units (RSUs). The initial grant is expected to represent
approximately 2% of the current issued share capital and is
expected to be made as soon as practicable after completion of the
Fundraising. The revised LTIP will have an overall limit of
10% of the issued share capital.
Conditions relating to the Fundraise
The Fundraise is conditional, inter
alia, upon:
a)
the Placing Agreement becoming unconditional in all respects (save
for Admission occurring) and not having been terminated in
accordance with its terms;
b)
Admission becoming effective by no later than 8.00 a.m. on
2 August 2024 (or such
later time and/or date as the Company and Joint Bookrunners may
agree (being not later than 8.00 a.m. on 9
August 2024).
Further details of the conditions of
the Placing and the Placing Agreement are set out in the Appendix,
under the heading 'Conditions of the Placing'.
Accordingly, if such conditions are
not satisfied or, if applicable, waived, the Fundraise will not
proceed.
The Fundraise is not underwritten by
Canaccord, Zeus Capital or any other person.
Settlement and dealings
The New Ordinary Shares will be in
registered form and will be capable of being held in either
certificated or uncertificated form (i.e. in CREST). Accordingly,
following Admission, settlement of transactions in the Ordinary
Shares may take place within the CREST system if a Shareholder so
wishes.
The ISIN number of the New Ordinary
Shares is GB00B125SX82. The TIDM is PANR.
Risk Factors
Any investment in the Company is
subject to a number of material risks and uncertainties.
Accordingly, prospective investors should carefully consider the
material operational, engineering, geological, commodity price,
political, financing, liquidity, foreign exchange, resource
estimation and other risks of investing in an AIM-quoted company
operating in the natural resources sector, other information
contained in this Announcement and any other publicly available
information about the Company before making a decision whether to
invest in the Company.
Before making an investment,
prospective investors are strongly advised to consult an investment
adviser authorised under the Financial Services and Markets Act
2000, as amended ("FSMA")
who specialises in investments of this kind. A prospective investor
should consider carefully whether an investment in the Company is
suitable in the light of his or her personal circumstances, the
financial resources available to him or her and his or her ability
to bear any loss which might result from such
investment.
IMPORTANT
INFORMATION
This Announcement is released by
Pantheon Resources plc and contains inside information for the
purposes of Article 7 of UK MAR. It is disclosed in accordance with
the Group's obligations under Article 17 of UK MAR.
No action has been taken by the
Group or the Joint
Bookrunners, or any of their respective
affiliates, that would, or which is intended to, permit a public
offer of the New Ordinary Shares in any jurisdiction or the
possession or distribution of this Announcement or any other
offering or publicity material relating to the New Ordinary Shares
in any jurisdiction where action for that purpose is required. Any
failure to comply with these restrictions may constitute a
violation of the securities laws of such jurisdictions. Persons
into whose possession this Announcement comes shall inform
themselves about, and observe, such restrictions.
No prospectus has been made
available in connection with the matters contained in this
Announcement and no such prospectus is required (in accordance with
the Prospectus Regulation) to be published.
The New Ordinary Shares will not be
admitted to trading on any stock exchange, other than the AIM
market operated by the London Stock Exchange.
Neither the content of the Company's
website nor any website accessible by hyperlinks on the Company's
website is incorporated in, or forms part of, this
Announcement.
In accordance with the AIM Rules -
Note for Mining and Oil & Gas Companies - June 2009, the
information contained in this Announcement has been reviewed and
signed off by Jay Cheatham, a qualified Chemical &
Petroleum Engineer, who has over 40 years' relevant experience
within the sector.
Information for Distributors
Solely for the purposes of the product governance requirements
contained within the FCA Handbook Product Intervention and Product
Governance Sourcebook (the "UK Product Governance Rules"), and
disclaiming all and any liability, whether arising in tort,
contract or otherwise, which any "manufacturer" (for the purposes
of the UK Product Governance Rules) may otherwise have with respect
thereto, the New Ordinary Shares have been subject to a product
approval process, which has determined that the New Ordinary Shares
are: (i) compatible with an end target market of investors who meet
the criteria of retail and professional clients and eligible
counterparties, each defined in the FCA Handbook Conduct of
Business Sourcebook ("COBS"); and (ii) eligible for distribution
through all distribution channels as are permitted by the UK
Product Governance Rules (the "UK Target Market
Assessment").
Solely for the purposes of the product governance requirements
contained within: (a) EU Directive 2014/65/EU on markets in
financial instruments, as amended ("MiFID II"); (b) Articles 9 and
10 of Commission Delegated Directive (EU) 2017/593 supplementing
MiFID II; and (c) local implementing measures (together, the "MiFID
II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which
any "manufacturer" (for the purposes of the Product Governance
Requirements) may otherwise have with respect thereto, the New
Ordinary Shares have been subject to a product approval process,
which has determined that such securities are: (i) compatible with
an end target market of investors who meet the criteria of retail
and professional clients and eligible counterparties, each as
defined in MiFID II; and (ii) eligible for distribution through all
distribution channels as are permitted by MiFID II (the "EU Target
Market Assessment").
Notwithstanding the UK Target Market Assessment and the EU
Target Market Assessment, distributors should note that: the price
of the New Ordinary Shares may decline and investors could lose all
or part of their investment; the New Ordinary Shares offer no
guaranteed income and no capital protection; and an investment in
New Ordinary Shares is compatible only with investors who do not
need a guaranteed income or capital protection, who (either alone
or in conjunction with an appropriate financial or other adviser)
are capable of evaluating the merits and risks of such an
investment and who have sufficient resources to be able to bear any
losses that may result therefrom. Each of the UK Target Market
Assessment and the EU Target Market Assessment is without prejudice
to the requirements of any contractual, legal or regulatory selling
restrictions in relation to the Proposals. Furthermore, it is noted
that, notwithstanding the UK Target Market Assessment
and the EU Target Market Assessment, the Joint Bookrunners will
only procure investors who meet the criteria of professional
clients and eligible counterparties, as defined under COBS or
MiFID II, as applicable.
For
the avoidance of doubt, neither the UK Target Market
Assessment nor the EU Target Market Assessment
constitutes: (a)
an assessment of suitability or appropriateness for the purposes
of Chapters 9A or 10A respectively of COBS or MiFID II, as
applicable; or (b) a recommendation to
any investor or group of investors to invest in, or purchase, or
take any other action whatsoever with respect to the New Ordinary
Shares pursuant to the Fundraise.
Each distributor is responsible for undertaking its own target
market assessment in respect of the New Ordinary Shares and
determining appropriate distribution channels.
IMPORTANT
NOTICES
MEMBERS OF THE PUBLIC ARE NOT
ELIGIBLE TO TAKE PART IN THE PLACING. THIS ANNOUNCEMENT (INCLUDING
THE APPENDIX) AND THE TERMS AND CONDITIONS SET OUT HEREIN
(TOGETHER, THIS "ANNOUNCEMENT") ARE DIRECTED ONLY AT
PERSONS WHOSE ORDINARY ACTIVITIES INVOLVE THEM IN ACQUIRING,
HOLDING, MANAGING AND DISPOSING OF INVESTMENTS (AS PRINCIPAL OR
AGENT) FOR THE PURPOSES OF THEIR BUSINESS AND WHO HAVE PROFESSIONAL
EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND ARE: (1) IF IN A
MEMBER STATE OF THE EUROPEAN ECONOMIC AREA ("EEA"), QUALIFIED INVESTORS AS DEFINED
IN THE PROSPECTUS REGULATION; AND/OR (2) IF IN THE UNITED KINGDOM,
QUALIFIED INVESTORS AS DEFINED IN THE PROSPECTUS REGULATION WHO (A)
FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT
2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE
"ORDER") (INVESTMENT
PROFESSIONALS) OR (B) FALL WITHIN ARTICLE 49(2)(a) TO (d) (HIGH NET
WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS, ETC.) OF THE ORDER;
OR (3) PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE
COMMUNICATED (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS
"RELEVANT
PERSONS").
THIS ANNOUNCEMENT AND THE
INFORMATION IN IT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO
ARE NOT RELEVANT PERSONS. PERSONS DISTRIBUTING THIS ANNOUNCEMENT
MUST SATISFY THEMSELVES THAT IT IS LAWFUL TO DO SO. ANY INVESTMENT
OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS
AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH
RELEVANT PERSONS. THIS ANNOUNCEMENT DOES NOT ITSELF CONSTITUTE AN
OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN PANTHEON
RESOURCES PLC.
THE NEW ORDINARY SHARES HAVE NOT
BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES
ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") OR WITH ANY SECURITIES
REGULATORY AUTHORITY OF ANY STATE OR JURISDICTION OF THE UNITED
STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR
INDIRECTLY, IN THE UNITED STATES EXCEPT PURSUANT TO AN APPLICABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE
WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER
JURISDICTION OF THE UNITED STATES. THE NEW ORDINARY SHARES ARE
BEING OFFERED AND SOLD ONLY OUTSIDE OF THE UNITED STATES IN
"OFFSHORE TRANSACTIONS"
WITHIN THE MEANING OF, AND IN ACCORDANCE WITH, REGULATION S UNDER
THE SECURITIES ACT AND WITHIN THE UNITED STATES TO CERTAIN
QUALIFIED INSTITUTIONAL BUYERS (WITHIN THE MEANING OF RULE 144A OF
THE SECURITIES ACT) OR ACCREDITED INVESTORS
AS DEFINED BY REGULATION D UNDER THE SECURITIES ACT
IN TRANSACTIONS NOT INVOLVING A PUBLIC ‎OFFERING
IN THE UNITED STATES. NEITHER THE UNITED STATES SECURITIES AND
EXCHANGE COMMISSION NOR ANY SECURITIES REGULATORY AUTHORITY OF ANY
STATE OR OTHER JURISDICTION OF THE UNITED STATES HAS APPROVED OR
DISAPPROVED OF AN INVESTMENT IN THE SECURITIES OR PASSED UPON OR
ENDORSED THE MERITS OF THE FUNDRAISE OR THE ACCURACY OR ADEQUACY OF
THE CONTENTS OF THIS ANNOUNCEMENT. ANY REPRESENTATION TO THE
CONTRARY IS A CRIMINAL OFFENCE IN THE UNITED STATES. NO PUBLIC
OFFERING OF THE NEW ORDINARY SHARES IS BEING MADE IN THE UNITED
STATES OR ELSEWHERE.
EACH PLACEE SHOULD CONSULT WITH ITS
OWN ADVISERS AS TO THE LEGAL, TAX, BUSINESS AND RELATED
IMPLICATIONS OF AN INVESTMENT IN THE NEW ORDINARY SHARES. THE PRICE
OF SHARES AND THE INCOME FROM THEM (IF ANY) MAY GO DOWN AS WELL AS
UP AND INVESTORS MAY NOT GET BACK THE FULL AMOUNT INVESTED ON A
DISPOSAL OF THEIR SHARES.
THIS ANNOUNCEMENT (INCLUDING THE
APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART,
DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES,
AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, , THE REPUBLIC OF SOUTH
AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION
OR DISTRIBUTION WOULD BE UNLAWFUL.
The distribution of this
Announcement and/or the Placing and/or the issue of the New
Ordinary Shares in certain jurisdictions may be restricted by law.
No action has been taken by the Company, the Joint Bookrunners or
any of their respective affiliates, agents, directors, officers or
employees that would permit an offer of the New Ordinary Shares or
possession or distribution of this Announcement or any other
offering or publicity material relating to such New Ordinary Shares
in any jurisdiction where action for that purpose is required.
Persons into whose possession this Announcement comes are required
by the Company and the Joint Bookrunners to inform themselves about
and to observe any such restrictions. Any failure to comply with
these restrictions may constitute a violation of the securities
laws of any ‎such
jurisdiction.‎
This Announcement or any part of it
does not constitute or form part of any offer to issue or sell, or
the solicitation of an offer to acquire, purchase or subscribe for,
any securities in the United States (including its territories and
possessions, any state of the United States and the District of
Columbia (the "United
States" or the "US")), Australia, Canada, Japan, New
Zealand, or the Republic of South Africa or any other jurisdiction
in which the same would be unlawful. No public offering of the New
Ordinary Shares is being made in any
jurisdiction.‎
This Announcement is not being
distributed by, nor has it been approved for the purposes of
section ‎‎21 of the Financial Services and Markets Act 2000, as
amended ("FSMA") by the
Joint Bookrunners or any other persons authorised under FSMA. This
Announcement is being distributed and ‎communicated to persons in
the United Kingdom only in circumstances in which section ‎‎21(1)
of FSMA does not apply or otherwise falls within a relevant
exemption. No prospectus will be ‎made available in connection with
the matters contained in this Announcement and no such ‎prospectus
is required (in accordance with the Prospectus Regulation) to be
published. Persons ‎needing advice should consult an independent
financial adviser.‎
This Announcement is only directed
at persons in Australia, who it is lawful to offer the shares to be
issued under the Placing without disclosure under Chapter 6D of the
Australian Corporations Act (including those who are "sophisticated
investors" as set out in section 708(8) of the Australian
Corporations Act or who are "professional investors" as set out in
section 708(11) of the Australian Corporations Act), and where such
action complies with all applicable laws, regulations and
directives and does not require any document to be lodged with the
Australian Securities and Investments Commission.
This Announcement is only directed
at persons in Singapore, who are: (a) "institutional investors" (as
defined in section 4A(1)(c) of the Securities and Futures Act 2001
of Singapore (the "SFA"));
or (b) a "relevant person" (as defined in section 275(2) of the
SFA); or (c) a person to whom an offer is being made, pursuant to
section 275(1A) of the SFA, in compliance with all applicable laws,
regulations and directives. Pursuant to section 309B of the SFA,
persons in Singapore are notified that the New Ordinary Shares are
"prescribed capital markets products" (as defined in the Securities
and Futures (Capital Markets Products) Regulations 2018 of
Singapore) and "Excluded Investment Products" (as defined in MAS
Notice SFA 04-N12: Notice on the Sale of Investment Products and
MAS Notice FAA-N16: Notice on Recommendations on Investment
Products).
The New Ordinary Shares have not
been approved or disapproved by the US Securities and Exchange
Commission, any state securities commission or other regulatory
authority in the United States, nor have any of the foregoing
authorities passed upon or endorsed the merits of the Fundraise or
the accuracy or adequacy of this Announcement. Any representation
to the contrary is a criminal offence in the United
States.
The relevant clearances have not
been, nor will they be, obtained from the securities commission of
any province or territory of Canada, no prospectus has been lodged
with, or registered by, the Australian Securities and Investments
Commission, the Japanese Ministry of Finance or the Financial
Markets Authority of New Zealand and the relevant clearances have
not been, and will not be, obtained for the South Africa Reserve
Bank or any other applicable body in the Republic of South Africa
in relation to the New Ordinary Shares and the New Ordinary Shares
have not been, nor will they be, registered under or offered in
compliance with the securities laws of any state, province or
territory of Australia, Canada, Japan, New Zealand or the Republic
of South Africa. Accordingly, the New Ordinary Shares may not
(unless an exemption under the relevant securities laws is
applicable) be offered, sold, resold or delivered, directly or
indirectly, in or into Australia, Canada, Japan, New Zealand or the
Republic of South Africa or any other jurisdiction outside the
United Kingdom.
Persons (including, without
limitation, nominees and trustees) who have a contractual right or
other legal obligations to forward a copy of this Announcement
should seek appropriate advice before taking any action.
By participating in the Placing,
each person who is invited to and who chooses to participate in the
Placing (a "Placee")
by making an oral and legally binding offer to acquire Placing
Shares will be deemed to have read and understood this Announcement
in its entirety, to be participating, making an offer and acquiring
Placing Shares on the terms and conditions contained herein and to
be providing the representations, warranties, indemnities,
acknowledgements and undertakings contained in the
Appendix.
This Announcement may contain
"forward-looking statements" with respect to certain of the
Company's plans and its current goals and expectations relating to
its future financial condition, performance, strategic initiatives,
objectives and results. Forward-looking statements sometimes use
words such as "aim", "anticipate", "target", "expect", "estimate",
"intend", "plan", "goal", "believe", "seek", "may", "could",
"outlook" or other words of similar meaning. By their nature, all
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances which are beyond the
control of the Company, including amongst other
things, risks associated with the oil
and gas industry in general (e.g. operational risks in exploration,
development and production; the uncertainty of reserve estimates;
and health, safety and environmental risks), constraint in the
availability of services or equipment, commodity price
fluctuations, changes in legislation impacting the oil and gas
industry, adverse weather conditions and uncertainties resulting
from potential delays or changes in plans with respect to
exploration or development projects or capital expenditures,
United Kingdom domestic and global economic
business conditions, market-related risks such as fluctuations in
interest rates and exchange rates, the policies and actions of
governmental and regulatory authorities, the effect of competition,
inflation, deflation, the timing effect and other uncertainties of
future acquisitions or combinations within relevant industries, the
effect of tax and other legislation and other regulations in the
jurisdictions in which the Company and its respective affiliates
operate, the effect of volatility in the equity, capital and credit
markets on the Company's profitability and ability to access
capital and credit, a decline in the Company's credit ratings; the
effect of operational risks; and the loss of key
personnel.
As a result, the actual future
financial condition, performance and results of the Company may
differ materially from the plans, goals and expectations set forth
in any forward-looking statements. Any forward-looking statements
made in this Announcement by or on behalf of the Company speak only
as of the date they are made. Except as required by applicable law
or regulation, the Company expressly disclaims any obligation or
undertaking to publish any updates or revisions to any
forward-looking statements contained in this Announcement to
reflect any changes in the Company's expectations with regard
thereto or any changes in events, conditions or circumstances on
which any such statement is based.
This Announcement does not identify
or suggest, or purport to identify or suggest, the risks (direct or
indirect) that may be associated with an investment in the New
Ordinary Shares. Any investment decision to subscribe New Ordinary
Shares in the Fundraise must be made solely on the basis of
information contained in this Announcement.
This Announcement has not been approved by any competent regulatory authority.
Canaccord is nominated adviser, sole broker and joint bookrunner to
the Company, authorised and regulated by the FCA in
the United Kingdom and is acting exclusively for the
Company and no one else in connection with the Placing and will not
regard any other person (whether or not a recipient of this
Announcement) as a client in relation to the Fundraise and
Admission or any other matters referred to in this Announcement and
Canaccord will not be responsible to anyone (including any Placees)
other than the Company for providing the protections afforded to
its clients or for providing advice in relation to the Fundraise,
Admission or any other matters referred to in this
Announcement.
Zeus Capital is joint bookrunner to
the Company, authorised and regulated by the FCA in
the United Kingdom and is acting exclusively for the
Company and no one else in connection with the Placing and will not
regard any other person (whether or not a recipient of this
Announcement) as a client in relation to the Fundraise and
Admission or any other matters referred to in this Announcement and
Zeus Capital will not be responsible to anyone (including any
Placees) other than the Company for providing the protections
afforded to its clients or for providing advice in relation to the
Fundraise, Admission or any other matters referred to in this
Announcement.
No representation or warranty,
express or implied, is or will be made as to, or in relation to,
and no ‎responsibility or liability
is or will be accepted by Canaccord,
Zeus Capital or by any of
their respective ‎affiliates or their affiliates'
agents, directors, officers and employees, respectively, as to, or
in relation to, the accuracy or
completeness of this Announcement or any other written or oral
‎information made available to or publicly
available to any interested party or its advisers, and any
‎liability therefor (whether in tort, contract or otherwise) is expressly
disclaimed.‎
The responsibilities of
Canaccord as the Company's Nominated Adviser under
the AIM Rules for Companies and the AIM Rules for Nominated
Advisers are owed solely to the London Stock Exchange and are not
owed to the Company or to any director or shareholder of the
Company or any other person, in respect of its decision to acquire
shares in the capital of the Company in reliance on any part of
this Announcement, or otherwise.
No statement in this Announcement or
in any previous announcement or in any previous presentation issued
by the Company was or is intended to be a profit forecast or
estimate, and no statement in this Announcement nor in any previous
announcement or in any previous presentation issued by the Company
should be interpreted to mean that earnings per share of the
Company for the current or future financial years would necessarily
match or exceed the historical published earnings per share of the
Company.
The price of shares and any income
expected from them may go down as well as up and investors may not
get back the full amount invested upon disposal of the shares. Past
performance is no guide to future performance, and persons needing
advice should consult an independent financial adviser.
This Announcement has been issued by, and is the sole
responsibility, of the Company. No representation or warranty
express or implied, is or will be made as to, or in relation to,
and no responsibility or liability is or will be accepted by
Canaccord, Zeus Capital or by any of their respective affiliates or
agents as to or in relation to, the accuracy or completeness of
this Announcement or any other written or oral information made
available to or publicly available to any interested party or its
advisers, and any liability therefore is expressly
disclaimed.
APPENDIX - TERMS AND
CONDITIONS OF THE PLACING
General
By participating in the Bookbuilding
Process and the Placing, each Placee will be deemed to have read
and understood this Announcement in its entirety, to be
participating, making an offer and acquiring Placing Shares on the
terms and conditions contained herein and to be providing the
representations, warranties, indemnities, acknowledgements and
undertakings contained in this Appendix. Upon being notified of its
allocation of Placing Shares, a Placee who chooses to participate
in the Placing by making an oral and legally binding offer shall be
contractually committed to acquire the number of placing shares
allocated to it and to the fullest extent permitted by law, will be
deemed to have agreed not to exercise any rights to rescind or
terminate or otherwise withdraw from such commitment.
Details of the Placing Agreement and the Placing
Shares
The Company and the
Joint Bookrunners have entered
into the Placing Agreement, pursuant to which, each of the
Joint Bookrunners have, subject to the terms and
conditions set out in that agreement, agreed to use reasonable
endeavours, as agents of the Company, to procure subscribers for
the Placing Shares pursuant to the Bookbuilding Process described
in this Announcement and as set out in the Placing
Agreement.
The Placing is conditional on the
Placing Agreement becoming unconditional and not being terminated
in accordance with its terms.
The Placing is not being
underwritten by either of the Joint Bookrunners.
The Placing Shares will, when
issued, be subject to the Articles, be credited as fully paid and
rank pari passu in all
respects with each other and with the New Ordinary Shares,
including the right to receive all dividends and other
distributions declared, made or paid in respect of the New Ordinary
Shares after Admission.
The Placing Shares will be issued
free of any encumbrance, lien or other security
interest.
Application for Admission
Application will be made to the
London Stock Exchange for the Placing Shares to be admitted to
trading on AIM. Subject to the satisfaction or waiver of the
conditions of the Placing Agreement (the "Conditions"), it is expected that
Admission will take place and dealings in the Placing Shares will
commence on AIM on or around 8.00 a.m. on 2 August 2024 (or such
later time and/or date as the Joint
Bookrunners and the
Company may agree in writing (being not
later than 8.00 a.m. on 9 August
2024))‎.
Bookbuilding Process
Commencing today, the Joint
Bookrunners will be conducting a Bookbuilding Process to determine
demand for participation in the Placing by Placees. This
Announcement gives details of the terms and conditions of, and the
mechanics of participation in, the Placing. However, the Joint
Bookrunners will be entitled to effect the Placing by such
alternative method to the Bookbuilding Process as it may, after
consultation with the Company, determine. No commissions will be
paid by or to Placees in respect of any participation in the
Placing or subscription for Placing Shares.
Participation in, and principal terms of, the Bookbuilding
Process
Participation in the Placing is by
invitation only and will only be available to persons who may
lawfully be, and are, invited to participate by the relevant Joint Bookrunner. The Joint
Bookrunners and the Joint Bookrunners' Affiliates (as defined
below) are entitled to participate as Placees in the Bookbuilding
Process.
The Bookbuilding Process will
establish the number of Placing Shares to be issued pursuant to the
Placing.
The Bookbuild has opened and will be
closed at the discretion of the Joint Bookrunners (in consultation
with the Company). A further announcement will be made by the
Company following the close of the Bookbuilding Process detailing
the number of Placing Shares to be subscribed for by the Placees at
the Issue Price (the "Placing
Results Announcement").
A bid in the Bookbuilding Process
will be made on the terms and conditions in this Announcement and
will be legally binding on the Placee on behalf of which it is made
and, except with the Joint Bookrunners' consent will not be capable
of variation or revocation after the close of the Bookbuilding
Process.
A Placee who wishes to participate
in the Bookbuilding Process should communicate its bid by telephone
to its usual sales contact at the appropriate Bookrunner. Each bid
should state the number of Placing Shares which the prospective
Placee wishes to subscribe for at the Issue Price. If successful,
the applicable Bookrunner will re-contact and confirm orally to
Placees following the close of the Bookbuilding Process the size of
their respective allocations and a trade confirmation will be
despatched as soon as possible thereafter. Oral confirmation from
the relevant Bookrunner of
the size of allocations and each Placee's oral commitments to
accept the same will constitute an irrevocable legally binding
agreement in favour of the Company and the relevant
Bookrunner pursuant to which each such Placee will
be required to accept the number of Placing Shares allocated to the
Placee at the Issue Price and otherwise on the terms and subject to
the conditions set out herein and in accordance with the Articles.
Each Placee's allocation and commitment will be evidenced by a
trade confirmation issued by the appropriate Bookrunner
to such Placee. The terms of this Appendix will be
deemed incorporated in that trade confirmation.
The Joint
Bookrunners reserve the right to scale back the
number of Placing Shares to be subscribed by any Placee, not to
accept offers to subscribe for Placing Shares or to accept such
offers in part rather than in whole. The acceptance and, if
applicable, scaling back of offers shall be at the absolute
discretion of the Joint Bookrunners,
after consultation with the Company.
Each Placee's obligations will be
owed to the Company and to the relevant
Bookrunner. Following the oral confirmation
referred to above, each Placee will also have an immediate,
separate, irrevocable and binding obligation, owed to the Company
and the relevant Bookrunner, as agent of
the Company, to pay to the relevant Bookrunner (or as the Bookrunner may direct) in
cleared funds an amount equal to the product of the Issue Price and
the number of Placing Shares allocated to such
Placee. Irrespective of the time at
which a Placee's allocation pursuant to the Placing is confirmed,
settlement for all Placing Shares to be acquired pursuant to the
Placing will be required to be made at the same time, on the basis
explained below under "Registration and Settlement".
To the fullest extent permissible by
law, neither the Joint Bookrunners nor any Joint Bookrunner Affiliate, nor any
person acting on their behalf shall have any liability to Placees
(or to any other person whether acting on behalf of a Placee or
otherwise). In particular, neither of the Joint Bookrunners,
any Joint Bookrunner
Affiliate, nor any person acting on their
behalf shall have any liability (including, to the extent legally
permissible, any fiduciary duties), in respect of its conduct of
the Bookbuilding Process or of such alternative method of effecting
the Placing as the Joint Bookrunners may determine.
All obligations of the Joint
Bookrunners under the Placing will be subject to fulfilment or
waiver of the conditions referred to in this Announcement
(including without limitation those referred to below under
"Conditions of the
Placing") and the Placing Agreement not having been
terminated in accordance with their terms. By participating in the Placing, each Placee agrees that its
rights and obligations in respect of the Placing will terminate
only in the circumstances described below and will not be capable
of rescission or termination by the Placee.
Conditions of the Placing
The Placing is conditional upon the
Placing Agreement becoming unconditional and not having been
terminated in accordance with its terms.
The obligations of the Joint
Bookrunners under the Placing Agreement are conditional, among
other things, upon:
(a)
the performance by the Company of its obligations
under the Placing Agreement to the extent that they fall to be
performed prior to Admission;
(b) the warranties
on the part of the Company contained in the Placing Agreement being
true and accurate on and as of the date of the Placing Agreement
and on Admission;
(c)
the Company having provided evidence satisfactory
to the Joint Bookrunners that they have received in cleared funds,
the proceeds of the Subscription by no later than 12.00 p.m. on the
Business Day prior to ‎Admission;
(d) the obligations
of the Joint Bookrunners not having been terminated pursuant to the
Placing Agreement and the Placing Agreement
otherwise becoming unconditional; and
(e)
Admission of the Placing Shares occurring not
later than 8.00 a.m. on 2
August 2024 or such later time and/or date as
the Joint Bookrunners and the Company may agree (but in any event
not later than 8.00 a.m. on 9 August 2024).
If (a) any of the Conditions of the
Placing Agreement are not fulfilled or to the extent permitted
under the Placing Agreement waived by the Joint Bookrunners; or (b)
the Placing Agreement is terminated in the circumstances specified
below, the Placing will lapse and each Placee's rights and
obligations hereunder shall cease and determine at such time and no
claim may be made by a Placee in respect thereof.
The Joint Bookrunners may, in their
absolute discretion and upon such terms as they think fit, waive
fulfilment of all or any of the conditions in the Placing Agreement
in whole or in part, or extend the time provided for fulfilment of
one or more conditions, save that certain conditions including the
condition relating to Admission may not be waived. Any such
extension or waiver will not affect Placees' commitments as set out
in this Appendix.
Neither of the Joint Bookrunners,
any Joint Bookrunner Affiliate, the Company, nor any subsidiary of
the Company, nor any branch, affiliate or associated undertaking of
any such company nor any of their respective directors, officers
and employees (each a "Pantheon
Affiliate") shall have any liability to any Placee (or to
any other person whether acting on behalf of a Placee or otherwise)
in respect of any decision it may make as to whether or not to
waive or to extend the time and/or date for the satisfaction of any
condition in the Placing Agreement or in respect of the Placing
generally.
By participating in the Placing,
each Placee agrees that the Joint Bookrunners' rights and
obligations in respect of the Placing terminate, inter alia, in the
circumstances described below under "Right to terminate under the Placing
Agreement".
Right to terminate under the Placing
Agreement
The Joint Bookrunners are entitled
to terminate the Placing Agreement in certain circumstances prior
to Admission, in particular, in the event that:
1.
any of the warranties given in the Placing
Agreement are not true and accurate when given at the date of the
Placing Agreement or would not be true and accurate when repeated,
which the Joint Bookrunners
consider to be material in the context of the
Placing;
2. the Company has
failed to comply, in any material respect, with its obligations
under the Placing Agreement, or with the requirements of any
applicable laws or regulations (including UK MAR and the AIM Rules)
in relation to the Placing;
3. there has been
any adverse change in, or any development reasonably likely to
involve a prospective adverse change in, or affecting, the
condition (financial, operational, legal or otherwise), earnings,
business, management, properties, assets, rights or results of
operations which is material in the context of the Company, taken
as a whole; or
4. there has been
a general moratorium on commercial banking activities in the United
Kingdom, a change or the introduction of any law, regulation or
policy which, in the reasonable opinion of the Joint Bookrunners,
is likely to materially and adversely affect the market's position
or prospects of the Company taken as a whole or any other crisis of
international or national effect or any change in any currency
exchange rates or controls or in any financial, political, economic
or market conditions or in market sentiment which, in any such
case, in the reasonable opinion of the Joint Bookrunners is
materially adverse.
By participating in the Placing,
each Placee agrees that the exercise by the Joint Bookrunners of
any right of termination or other discretion under the Placing
Agreement shall be within the absolute discretion of the Joint
Bookrunners and that the Joint Bookrunners need not make any
reference to the Placees in this regard and that, to the fullest
extent permitted by law, neither the Company, neither of the Joint
Bookrunners, any Joint Bookrunner Affiliate, nor any Pantheon
Affiliate shall have any liability whatsoever to the Placees in
connection with any such exercise or failure to so
exercise.
No
Admission Document or Prospectus
No admission document, offering
document or prospectus has been or will be prepared in relation to
the Placing and no such prospectus is required (in accordance with
the Prospectus Regulation) to be published or submitted to be
approved by the FCA and Placees' commitments will be made solely on
the basis of the information contained in this Announcement and in
any Exchange Information.
Each Placee, by accepting a
participation in the Placing, agrees that the content of this
Announcement is exclusively the responsibility of the Company and
confirms to the Joint Bookrunners and the Company that it has not
relied on any information, representation, warranty or statement
made by or on behalf of the Joint Bookrunners (other than the
amount of the relevant Placing participation in the oral
confirmation given to Placees and the trade confirmation referred
to below), any Joint Bookrunner Affiliate, any persons acting on
their behalf or the Company or any Pantheon Affiliate and neither
of the Joint Bookrunners, any Joint Bookrunner Affiliate, any
persons acting on their behalf, the Company, any Pantheon Affiliate
nor any persons acting on their behalf will be liable for the
decision of any Placee to participate in the Placing based on any
other information, representation, warranty or statement which the
Placee may have obtained or received (regardless of whether or not
such information, representation, warranty or statement was given
or made by or on behalf of any such persons). By participating in
the Placing, each Placee acknowledges to and agrees with the Joint
Bookrunners for itself and as agent for the Company that, except in
relation to the information contained in this Announcement, it has
relied on its own investigation of the business, financial or other
position of the Company in deciding whether to participate in the
Placing. Nothing in this paragraph shall exclude the liability of
any person for fraudulent misrepresentation.
Registration and settlement
Settlement of transactions in the
Placing Shares following Admission will take place within the CREST
system, using the delivery versus payment mechanism, subject to
certain exceptions. The Joint Bookrunners reserve the right to
require settlement for and delivery of the Placing Shares to
Placees by such other means as they may deem necessary, including,
without limitation, if delivery or settlement is not possible or
practicable within the CREST system within the timetable set out in
this Announcement or would not be consistent with the regulatory
requirements in the Placee's jurisdiction.
The expected timetable for
settlement will be as follows:
Trade Date
|
26 July 2024
|
Settlement Date
|
2 August 2024
|
ISIN Code
|
GB00B125SX82
|
SEDOL
|
B125SX8
|
Deadline for input instruction into
CREST
|
2 August 2024
|
CREST ID for Canaccord
CREST ID for
Zeus
|
805
601/WRCLT
|
Each Placee allocated Placing Shares
in the Placing will be sent a trade confirmation stating the number
of Placing Shares allocated to it, the Issue Price, the aggregate
amount owed by such Placee (in pounds sterling) to the Joint
Bookrunners and settlement instructions. Placees should settle
against the appropriate Bookrunner's CREST ID shown above. It is
expected that such trade confirmation will be despatched on the
expected trade date shown above. Each Placee agrees that it will do
all things necessary to ensure that delivery and payment is
completed in accordance with either the standing CREST or
certificated settlement instructions which it has in place with the
appropriate Bookrunner.
It is expected that settlement will
take place on the Settlement Date shown above on a delivery versus
payment basis in accordance with the instructions set out in the
trade confirmation unless otherwise notified by the relevant
Bookrunner.
Interest is chargeable daily on
payments not received from Placees on the due date in accordance
with the arrangements set out above at the rate of two percentage
points above the base rate of HSBC Bank Plc.
Each Placee is deemed to agree that
if it does not comply with these obligations, the Joint Bookrunners
may sell any or all of the Placing Shares allocated to the Placee
on such Placee's behalf and retain from the proceeds, for the
Company's own account and profit, an amount equal to the aggregate
amount owed by the Placee plus any interest due. The Placee will,
however, remain liable for any shortfall below the aggregate amount
owed by such Placee and it may be required to bear any stamp duty
or stamp duty reserve tax (together with any interest or penalties)
which may arise upon the sale of such Placing Shares on such
Placee's behalf and shall indemnify the Joint Bookrunners and the
Company on demand in respect of any such amounts.
If Placing Shares are to be
delivered to a custodian or settlement agent, the Placee should
ensure that the trade confirmation is copied and delivered
immediately to the relevant person within that
organisation.
Insofar as Placing Shares are
registered in the Placee's name or that of its nominee or in the
name of any person for whom the Placee is contracting as agent or
that of a nominee for such person, such Placing Shares will,
subject as provided below, be so registered free from any liability
to any levy, stamp duty or stamp duty reserve tax. If there are any
circumstances in which any other stamp duty or stamp duty reserve
tax is payable in respect of the issue of the Placing Shares,
neither the Joint Bookrunners nor the Company shall be responsible
for the payment thereof. Placees will not be entitled to receive
any fee or commission in connection with the Placing.
Representations, warranties and further
terms
By participating in the Placing,
each Placee (and any person acting on such Placee's
behalf):
1.
represents and warrants that it has read and
understood this Announcement in its entirety (including this
Appendix) and acknowledges that its participation in the Placing
and the issue of the Placing Shares will be governed by the terms
of this Announcement (including this Appendix);
2.
acknowledges that no prospectus, admission
document or offering document has been or will be prepared in
connection with the Placing and it has not received and will not
receive a prospectus or other offering document in connection with
the Bookbuilding Process, the Placing or the Placing
Shares;
3.
agrees to indemnify on an after-tax basis and hold
harmless each of the Company, the Joint Bookrunners, Joint
Bookrunner Affiliates and Pantheon Affiliates and any person acting
on their behalf from any and all costs, losses, claims, liabilities
and expenses (including legal fees and expenses) arising out of or
in connection with any breach of the representations, warranties,
acknowledgements, agreements and undertakings in this Announcement
and further agrees that the provisions of this Announcement shall
survive after completion of the Placing;
4.
acknowledges that the Placing Shares will be
admitted to trading on AIM and the Company is therefore required to
publish and has published certain business and financial
information in accordance with the AIM Rules and UK MAR and other
applicable laws and regulations (the "Exchange Information"), which includes
the Company's announcements and circulars published in the past 12
months, and that the Placee is able to obtain or access this
Exchange Information, without undue difficulty, and is aware of the
contents of the Exchange Information;
5.
acknowledges that its obligations are irrevocable and legally
binding and shall not be capable of rescission or termination by it
in any circumstances;
6. agrees that it
has no rights against the Joint Bookrunners or the Company, or any
of their respective officers, directors or employees, under the
Placing Agreement pursuant to the Contracts (Rights of Third
Parties Act) 1999 and that the exercise by the Joint Bookrunners of
any right of termination or other discretion under the Placing
Agreement shall be within the absolute discretion of the Joint
Bookrunners and that the Joint Bookrunners need not make any
reference to the Placees in this regard and that, to the fullest
extent permitted by law, neither the Company, the Joint
Bookrunners, any Joint Bookrunner Affiliate nor any Pantheon
Affiliate shall have any liability whatsoever to the Placees in
connection with any such exercise or failure to so
exercise;
7.
acknowledges that neither Joint Bookrunners, any
Joint Bookrunner Affiliate, or any person acting on their behalf
has provided, and will not provide, it with any material or
information regarding the Placing Shares or the Company; nor has it
requested any Joint Bookrunner, nor any Joint Bookrunner Affiliate,
nor any person acting on their behalf to provide it with any such
material or information;
8.
acknowledges that (i) neither of the Joint
Bookrunners or any Joint Bookrunner Affiliate, or any person acting
on behalf of any of them is making any recommendations to it,
advising it regarding the suitability of any transactions it may
enter into in connection with the Placing and that participation in
the Placing is on the basis that it is not and will not be a client
of either of the Joint Bookrunners and that the Joint Bookrunners
do not have any duties or responsibilities to it (or any person
acting on behalf of a Placee) for providing the protections
afforded to its clients or for providing advice in relation to the
Placing nor in respect of any representations, warranties,
agreements, undertakings or indemnities contained in the Placing
Agreement nor for the exercise or performance of any of its rights
and obligations thereunder including any rights to waive or vary
any conditions or exercise any termination right, and (ii) neither
it nor, as the case may be, its clients expect the Joint
Bookrunners to have any duties or responsibilities to it similar or
comparable to the duties of "best execution" and "suitability"
imposed by the Conduct of Business Sourcebook contained in the
FCA's Handbook of Rules and Guidance, and that the Joint
Bookrunners are not acting for it or its clients, and that the
Joint Bookrunners will not be responsible to any person other than
the Company for providing protections afforded to its
clients;
9.
acknowledges that the content of this Announcement
is exclusively the responsibility of the Company and that neither
of the Joint Bookrunners, nor any Joint Bookrunner Affiliate, nor
any person acting on their behalf will be responsible for or shall
have any liability for any information, representation or statement
relating to the Company contained in this Announcement or any
information previously published by or on behalf of the Company and
neither of the Joint Bookrunners, nor any Joint Bookrunner
Affiliate, nor any person acting on their behalf will be liable for
any Placee's decision to participate in the Placing based on any
information, representation or statement contained in this
Announcement or otherwise. Each Placee further represents, warrants
and agrees that the only information on which it is entitled to
rely and on which such Placee has relied in committing to subscribe
for the Placing Shares is contained in this Announcement and the
Exchange Information, such information being all that it deems
necessary to make an investment decision in respect of the Placing
Shares, and that it has relied on its own investigation with
respect to the Placing Shares and the Company in connection with
its decision to subscribe for the Placing Shares and acknowledges
that it is not relying on any other information whatsoever and in
particular it is not relying on any investigation that the Joint
Bookrunners, any Joint Bookrunner Affiliate, or any person acting
on their behalf may have conducted with respect to the Placing
Shares or the Company and none of such persons has made any
representations to it, express or implied, with respect
thereto;
10. acknowledges: (i) it has sufficient knowledge and experience
in financial, business and international investment matters as is
required to evaluate the merits and risks of subscribing for the
Placing Shares; (ii) that it is experienced in investing in
securities of this nature and is aware that it may be required to
bear, and is able to bear, the economic risk of, and is able to
sustain, a complete loss in connection with the Placing; (iii) it
has had sufficient time to consider and conduct its own
investigation in connection with its subscription for the Placing
Shares, including all tax, legal and other economic considerations;
and (iv) it has relied upon its own examination of, and due
diligence on, the Company, and the terms of the Placing, including
the merits and risks involved;
11. unless paragraph 12 applies, represents and warrants that it
has neither received nor relied on any inside information for the
purposes of UK MAR and section 56 of the Criminal Justice Act 1993
("CJA") in relation to the
Company or its participation in the Placing;
12. it acknowledges and
agrees that, if it has received any inside information (for the
purpose of UK MAR and section 56 of the CJA) in relation to the
Company and its securities in advance of the Placing, it has
consented to receive inside information for the purposes of UK MAR
and the CJA and it acknowledges that it was an insider or a person
who has received a market sounding for the purpose of such
legislation and it confirms that it has not: (a) dealt (or
attempted to deal) in the securities of the Company (or cancelled
or amended an order in relation thereto); (b) encouraged,
recommended or induced another person to deal in the securities of
the Company (or to cancel or amend an order in relation thereto);
(c) unlawfully disclosed inside information to any person, in each
case, prior to the information being made publicly
available;
13. acknowledges that it is not entitled to rely on any
information (including, without limitation, any information
contained in any management presentation given in relation to the
Placing) other than that contained in this Announcement (including
this Appendix) and in any Exchange Information and represents and
warrants that it has not relied on any representations relating to
the Placing, the Placing Shares or the Company other than the
information contained in this Announcement or in any Exchange
Information;
14. acknowledges that: it has not relied on any information
relating to the Company contained in any research reports prepared
by either of the Joint Bookrunners or any Joint Bookrunner
Affiliate, or any person acting on their behalf and understands
that (i) none of the Joint Bookrunners, nor any Joint Bookrunner
Affiliate, nor any person acting on their behalf has or shall have
any liability for any public information relating to the Company or
otherwise or any representation; (ii) none of the Joint
Bookrunners, nor any Joint Bookrunner Affiliate, nor any person
acting on their behalf has or shall have any liability for any
additional information that has otherwise been made available to
such Placee, whether at the date of publication, the date of this
Announcement or otherwise; and that (iii) none of the Joint
Bookrunners, nor any Joint Bookrunner Affiliate, nor any person
acting on their behalf makes any representation or warranty,
express or implied, as to the truth, accuracy or completeness of
such information, whether at the date of publication, the date of
this Announcement or otherwise;
15. represents and warrants that (i) it is permitted to acquire
the Placing Shares for which it is subscribing under the laws and
regulations of all relevant jurisdictions which apply to it; (ii)
it has fully observed such laws and regulations and obtained all
such governmental and other guarantees and other consents and
authorities which may be required or necessary in connection with
its subscription for Placing Shares and its participation in the
Placing and has complied with all other necessary formalities in
connection therewith; (iii) it has all necessary capacity to commit
to participation in the Placing and to perform its obligations in
relation thereto and will honour such obligations; (iv) it has paid
any issue, transfer or other taxes due in connection with its
subscription for Placing Shares and its participation in the
Placing in any territory; and (v) it has not taken any action which
will or may result in the Company, the Joint Bookrunners or any
Joint Bookrunner Affiliate, or Pantheon Affiliate or any person
acting on their behalf being in breach of the legal and/or
regulatory requirements of any territory in connection with the
Placing;
16. represents and warrants that it understands that the Placing
Shares have not been and will not be registered under the
Securities Act or under the securities laws of any state or other
jurisdiction of the United States and are not being offered or sold
within the United States, except pursuant to an exemption from, or
in a transaction not subject to, the registration requirements of
the Securities Act;
17. represents and
warrants that it and the person(s), if any, for whose account or
benefit it is subscribing for the Placing Shares is not subscribing
for and/or purchasing Placing Shares as a result of any "directed
selling efforts" in the United States as defined in Regulation
S;
18. represents and
warrants that it and the person(s), if any, for whose account or
benefit it is subscribing for the Placing Shares is subscribing for
the Placing Shares for investment purposes and is not acquiring
Placing Shares with a view to the offer, sale, resale, transfer,
delivery or distribution, directly or indirectly, of any Placing
Shares into the United States;
19. represents and
warrants that it and the person(s), if any, for whose account or
benefit it is subscribing for Placing Shares is, and at the time it
subscribes for the Placing Shares will be either (a) outside the
United States of America and acquiring the Placing Shares in an
"offshore transaction" as defined in and pursuant to Regulation S;
or (b) if in the United States of America, a qualified
institutional buyer within the meaning of Rule 144A under the
Securities Act and will have duly executed an investor letter in
the form provided to it;
20. represents and
warrants that it has not, directly or indirectly, distributed,
forwarded, transferred or otherwise
transmitted, and will not, directly or indirectly, distribute,
forward, transfer or otherwise transmit, any presentation or
offering materials concerning the Placing or the Placing Shares to
any persons within the United States of America;
21. represents and
warrants that it will not distribute any document relating to the
Placing Shares and it will be acquiring the
Placing Shares for its own account as principal or for a
discretionary account or accounts (as to which it has the authority
to make the statements set out herein) for investment purposes only
and it does not have any contract, understanding or arrangement
with any person to sell, pledge, transfer or grant a participation
therein to such person or any third person with respect of any
Placing Shares;
22. represents and warrants that it will not offer or sell,
directly or indirectly, any of the Placing Shares in the United
States except in accordance with Regulation S or pursuant to an
exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act;
23. represents and warrants that, where it is resident in
Australia, it is a person who it is lawful to offer the shares to
be issued under the Placing without disclosure under Chapter 6D of
the Australian Corporations Act (including those who are
"sophisticated investors" as set out in section 708(8) of the
Australian Corporations Act or who are "professional investors" as
set out in section 708(11) of the Australian Corporations Act), and
it acknowledges that no document is being lodged with
ASIC;
24. represents and warrants that, where it is resident in
Singapore, it is: (a) an "institutional
investor" (as defined in section 4A(1)(c) of the Securities and
Futures Act 2001 of Singapore (the "SFA")); or (b) a "relevant person" (as
defined in section 275(2) of the SFA); or (c) a person to whom an
offer is being made, pursuant to section 275(1A) of the SFA, in
compliance with all applicable laws, regulations and directives and
that it understands (i) pursuant to section 309B of the SFA, that
the Placing Shares are "prescribed capital markets products" (as
defined in the Securities and Futures (Capital Markets Products)
Regulations 2018 of Singapore) and "Excluded Investment Products"
(as defined in MAS Notice SFA 04-N12: Notice on the Sale of
Investment Products and MAS Notice FAA-N16: Notice on
Recommendations on Investment Products); and (ii)
there are on-sale restrictions in Singapore that
may be applicable to investors who acquire Placing Shares. As such,
investors are advised to consider carefully whether the investment
is suitable for them and seek independent professional advice to
acquaint themselves with the SFA provisions relating to resale
restrictions in Singapore and comply accordingly;
25. represents and warrants that, if it is a financial
intermediary, as that term is used in Article 5(1) of the
Prospectus Regulation, the Placing Shares purchased by it in the
Placing will not be acquired on a non-discretionary basis on behalf
of, nor will they be acquired with a view to their offer or resale
to, persons in a member state of the European Economic Area which
has implemented the Prospectus Regulation other than "qualified
investors" as defined in Article 2(e) of the Prospectus Regulation;
or persons in the United Kingdom other than "qualified investors"
as defined in Article 2(e) of the Prospectus Regulation; or in
circumstances in which the prior consent of the Joint Bookrunners
has been given to such an offer or resale;
26. represents and warrants that it has not offered or sold and
will not offer or sell any Placing Shares: (i) to the public in any
member state of the European Economic Area or (ii) to the public in
the United Kingdom, except (in each case) in circumstances falling
within Article 1(4) of the Prospectus Regulation which do not
result in any requirement for the publication of a prospectus
pursuant to Article 3 of the Prospectus Regulation;
27. represents and
warrants that it has only communicated or caused to be communicated
and will only communicate or cause to be communicated any
invitation or inducement to engage in investment activity (within
the meaning of section 21 of FSMA) relating to the Placing Shares
in circumstances in which it is permitted to do so pursuant to
section 21 of FSMA and it acknowledges and agrees that this
Announcement has not been approved by the Joint Bookrunners in
their capacity as authorised persons under section 21 of FSMA and
it may not therefore be subject to the controls which would apply
if it was made or approved as financial promotion by an authorised
person;
28. represents and warrants that it has complied and will comply
with all applicable provisions of FSMA with respect to anything
done by it in relation to the Placing Shares in, from or otherwise
involving, the United Kingdom;
29. represents and warrants: (i) that it has complied, and will
comply, with its obligations under the laws and regulations of all
relevant jurisdictions which apply to it (including, where
applicable, the CJA and MAR, the Criminal Justice Act 1988, the
Terrorism Act 2000, the Anti-Terrorism, Crime and Security Act
2001, the Proceeds of Crime Act 2002 (as amended), the Terrorism
Act 2006, the Counter-Terrorism Act 2008 and the Money Laundering,
Terrorist Financing and Transfer of Funds (Information on the
Payer) Regulations 2017, as amended and the Senior Management
Arrangements, Systems and Controls (SYSC) Sourcebook of the FCA)
and, to the extent applicable, any subordinate legislation and
related or similar rules, regulations of any body having
jurisdiction in respect thereof (and, if it is making payment on
behalf of a third party, that satisfactory evidence has been
obtained and recorded by it to verify the identity of the third
party); and (ii) that it is not a person: (a) with whom
transactions are prohibited under the Foreign Corrupt Practices Act
1977 or any economic sanction programmes administered by, or
regulations promulgated by, the Office of Foreign Assets Control of
the U.S. Department of the Treasury; (b) named on the Consolidated
List of Financial Sanctions Targets maintained by HM
Treasury of the United Kingdom, the U.S. Commerce Department Bureau of Industry and Security
Denied Persons List, Entity List or Unverified List, the U.S.
Treasury Department Office of Foreign Asset Controls Specially
Designated National and Blocked Persons List or the U.S. State
Department Directorate of Defense Trade Controls Debarred Parties
List; or (c) subject to financial sanctions imposed pursuant to a
regulation of the European Union or a regulation adopted by
the United Nations ((i) and (ii), together, the "Regulations");
30. if in the United Kingdom, represents and warrants that: (a) it
is a person having professional experience in matters relating to
investments who falls within the definition of "investment
professionals" in Article 19(5) of the FPO, or (b) it is a person
who falls within Article 49(2) (a) to (d) ("High Net Worth
Companies, Unincorporated Associations etc") of the FPO, and (c) it
is a qualified investor as defined in Article 2(e) of the
Prospectus Regulation, acting as principal or in circumstances to
which section 86(2) of FSMA applies, and (d) it is person to whom
this Announcement may otherwise lawfully be
communicated;
31. represents and warrants that its participation in the Placing
would not give rise to an offer being required to be made by it or
any person with whom it is acting in concert pursuant to Rule 9 of
the City Code on Takeovers and Mergers;
32. undertakes that it (and any person acting on its behalf) will
pay for the Placing Shares acquired by it in accordance with this
Announcement and with any trade confirmation sent by the
appropriate Bookrunner (or on its behalf) to it in respect of its
allocation of Placing Shares and their participation in the Placing
on the due time and date set out therein (or as otherwise notified
by the Joint Bookrunners) against delivery of such Placing Shares
to it, failing which the relevant Placing Shares may be placed with
other Placees or sold as the Joint Bookrunners may, in their
absolute discretion, determine and it will remain liable for any
shortfall below the net proceeds of such sale and the placing
proceeds of such Placing Shares and may be required to bear any
stamp duty or stamp duty reserve tax (together with any interest or
penalties due pursuant to the terms set out or referred to in this
Announcement) which may arise upon the sale of such Placee's
Placing Shares on its behalf and shall indemnify on an after-tax
basis and hold harmless the Company and the Joint Bookrunners in
the event that any of the Company or any Pantheon Affiliate or the
Joint Bookrunners or any Joint Bookrunner Affiliate has incurred
any such liability to stamp duty or stamp duty reserve
tax;
33. acknowledges that neither of the Joint Bookrunners, nor any
Joint Bookrunner Affiliate nor any person acting on their behalf is
making any recommendations to it or advising it regarding the
suitability or merits of any transaction it may enter into in
connection with the Placing, and acknowledges that no Joint
Bookrunner, nor any Joint Bookrunner Affiliate nor any person
acting on their behalf has any duties or responsibilities to it for
providing advice in relation to the Placing or in respect of any
representations, warranties, undertakings or indemnities contained
in the Placing Agreement or for the exercise or performance of any
of the Joint Bookrunners' rights and obligations thereunder,
including any right to waive or vary any condition or exercise any
termination right contained therein;
34. undertakes that (i) the person whom it specifies for
registration as holder of the Placing Shares will be (a) the Placee
or (b) the Placee's nominee, as the case may be, (ii) neither the
Joint Bookrunners nor the Company will be responsible for any
liability to stamp duty or stamp duty reserve tax resulting from a
failure to observe this requirement and (iii) the Placee and any
person acting on its behalf agrees to acquire the Placing Shares on
the basis that the Placing Shares will be allotted to the CREST
stock account of the appropriate Joint Bookrunner which will hold
them as settlement agent as nominee for the Placee until settlement
in accordance with its standing settlement instructions with
payment for the Placing Shares being made simultaneously upon
receipt of the Placing Shares in the Placee's stock account on a
delivery versus payment basis;
35. acknowledges that it irrevocably appoints any director of the
appropriate Joint Bookrunner as its agent for the purposes of
executing and delivering to the Company and/or its registrars any
documents on its behalf necessary to enable the Placing Shares
allocated to it and agreed to be taken up by it under the Placing
to be credited to the CREST stock account it has specified or for
it to be registered as the holder of any of the Placing Shares
allocated to it and agreed to be taken up by it under the
Placing;
36. represents and warrants that it is not a resident of Canada,
Japan, New Zealand or the Republic of South Africa and acknowledges
that the Placing Shares have not been and will not be registered
nor will a prospectus be approved, registered or published in
respect of the Placing Shares under the securities legislation of
any Restricted Jurisdiction and, subject to certain exceptions, may
not be offered, sold, taken up, renounced, delivered or
transferred, directly or indirectly, within any Restricted
Jurisdiction;
37. represents and warrants that any person who confirms to the
appropriate Joint Bookrunner on behalf of a Placee an agreement to
subscribe for Placing Shares and/or who authorises the Joint
Bookrunners to notify the Placee's name to the Company's registrar,
has authority to do so on behalf of the Placee;
38. acknowledges that the agreement to settle each Placee's
acquisition of Placing Shares (and/or the acquisition of a person
for whom it is contracting as agent) free of stamp duty and stamp
duty reserve tax depends on the settlement relating only to an
acquisition by it and/or such person direct from the Company of the
Placing Shares in question. Such agreement assumes that the Placing
Shares are not being acquired in connection with arrangements to
issue depositary receipts or to issue or transfer the Placing
Shares into a clearance service. If there were any such
arrangements, or the settlement related to other dealing in the
Placing Shares, stamp duty or stamp duty
reserve tax may be payable, for which neither the Company nor
the Joint Bookrunners will be responsible.
If this is the case, the Placee should take its own advice and
notify the appropriate Joint Bookrunner
accordingly;
39. acknowledges that
when a Placee or any person acting on behalf of the Placee is
dealing with a Joint Bookrunner, any money
held in an account with a Joint Bookrunner
on behalf of the Placee and/or any person acting on behalf of the
Placee will not be treated as client money within the meaning of
the relevant rules and regulations of the FCA and that the money
will not be subject to the protections conferred by the client
money rules; as a consequence, this money will not be segregated in
accordance with the client money rules and will be
used by a Joint Bookrunner in the course of its business; and the
Placee will rank only as a general creditor of the Joint Bookrunner
(as the case may be);
40. acknowledges and agrees that in order to ensure compliance
with the Regulations, the Joint Bookrunners (each for themselves
and as agents on behalf of the Company) or the Company's registrars
may, in their absolute discretion, require verification of its
identity. Pending the provision to the appropriate Joint Bookrunner
or the Company's registrars, as applicable, of evidence of
identity, definitive certificates in respect of the Placing Shares
may be retained at the Bookrunner's absolute discretion or, where
appropriate, delivery of the Placing Shares to it in uncertificated
form may be delayed at the Bookrunner's or the Company's
registrars', as the case may be, absolute discretion. If within a
reasonable time after a request for verification of identity the
Bookrunner (for itself and as agent on behalf of the Company) or
the Company's registrars have not received evidence satisfactory to
them, the Joint Bookrunners and/or the Company may, at its absolute
discretion, terminate its commitment in respect of the Placing, in
which event the monies payable on acceptance of allotment will, if
already paid, be returned without interest to the account of the
drawee's bank from which they were originally debited;
41. acknowledges that the basis of allocation will be determined
by the Joint Bookrunners and the Company at their absolute
discretion and that the right is reserved to reject in whole or in
part and/or scale back any participation in the Placing;
42. irrevocably authorises the Company and the Joint Bookrunners
to produce this Announcement pursuant to, in connection with, or as
may be required by any applicable law or regulation, administrative
or legal proceeding or official inquiry with respect to the matters
set forth herein;
43. acknowledges and agrees that its commitment to subscribe for
Placing Shares on the terms and conditions set out herein will
continue notwithstanding any amendment that may in future be made
to the terms of the Placing and that Placees will have no right to
be consulted or require that their consent be obtained with respect
to the Company's or the Joint Bookrunners' conduct of the
Placing;
44. acknowledges and agrees that time is of the essence as regards
its obligations under this Appendix;
45. acknowledges and agrees that any document that is to be sent
to it in connection with the Placing will be sent at its risk and
may be sent to it at any address provided by it to the Joint
Bookrunners;
46. acknowledges and agrees that it will be bound by the terms of
the Articles and that it will (or will
procure that its nominee will) if applicable, make notification to
the Company of the interest in its Ordinary Shares in accordance
with the requirements of Chapter 5 of the Disclosure Guidance and
Transparency Rules of the FCA;
47. acknowledges and agrees that these terms and conditions in
this Appendix and all documents into which this Appendix is
incorporated by reference or otherwise validly forms a part and/or
any agreements entered into pursuant to these terms and conditions
and all agreements to acquire Placing Shares pursuant to the
Placing and any non-contractual obligations arising out of or in
connection with such agreements will be governed by and construed
in accordance with the laws of England and Wales and it submits (on
behalf of itself and on behalf of any person on whose behalf it is
acting) to the exclusive jurisdiction of the courts of England and
Wales in relation to any claim, dispute or matter arising out of or
in connection with any such agreements and any non-contractual
obligations arising out of or in connection with such agreements,
except that enforcement proceedings in respect of the obligation to
make payment for the Placing Shares (together with any interest
chargeable thereon) may be taken by the Company or the Joint
Bookrunners in any jurisdiction in which the relevant Placee is
incorporated or in which any of its securities have a quotation on
a recognised stock exchange; and
48. acknowledges and
understands that the Company, the Joint Bookrunners, and others
will rely upon the truth and accuracy of the foregoing
representations, warranties, agreements, undertakings and
acknowledgements.
The acknowledgements, agreements,
undertakings, representations and warranties referred to above are
given to each of the Company and the Joint Bookrunners (for their
own benefit and, where relevant, the benefit of any Joint
Bookrunner Affiliate or Pantheon Affiliate and any person acting on
their behalf) and are irrevocable.
No claim shall be made against the
Company, the Joint Bookrunners, any Joint Bookrunner Affiliate, any
Pantheon Affiliate, or any other person acting on behalf of any of
such persons by a Placee to recover any damage, cost, loss, charge
or expense which it may suffer or incur by reason of or arising
from or in connection with the performance of its obligations
hereunder or otherwise howsoever in connection with the Placing or
Admission, to the extent permitted under English law.
No UK stamp duty or stamp duty
reserve tax should be payable to the extent that the Placing Shares
are issued or transferred (as the case may be) into CREST to, or to
the nominee of, a Placee who holds those shares beneficially (and
not as agent or nominee for any other person) within the CREST
system and registered in the name of such Placee or such Placee's
nominee.
Any arrangements to issue or
transfer the Placing Shares into a depositary receipts system or a
clearance service or to hold the Placing Shares as agent or nominee
of a person to whom a depositary receipt may be issued or who will
hold the Placing Shares in a clearance service, or any arrangements
subsequently to transfer the Placing Shares, may give rise to stamp
duty and/or stamp duty reserve tax, for which neither the Company
nor either of the Joint Bookrunners will be responsible and the
Placee to whom (or on behalf of whom, or in respect of the person
for whom it is participating in the Placing as an agent or nominee)
the allocation, allotment, issue or delivery of Placing Shares has
given rise to such stamp duty or stamp duty reserve tax undertakes
to pay such stamp duty or stamp duty reserve tax forthwith and to
indemnify on an after-tax basis and to hold harmless the Company
and the Joint Bookrunners in the event that any of the Company or
any Pantheon Affiliate or the Joint Bookrunners or any Joint
Bookrunner Affiliate has incurred any such liability to stamp duty
or stamp duty reserve tax.
In addition, Placees should note
that they will be liable for any capital duty, stamp duty and all
other stamp, issue, securities, transfer, registration, documentary
or other duties or taxes (including any interest, fines or
penalties relating thereto) payable outside the UK by them or any
other person on the acquisition by them of any Placing Shares or
the agreement by them to acquire any Placing Shares.
References to time in this
Announcement are to London time, unless otherwise stated. All times
and dates in this Announcement may be subject to amendment. The
Joint Bookrunners shall notify the Placees and any person acting on
behalf of the Placees of any such changes.
This Announcement has been issued by
the Company and is the sole responsibility of the
Company.
Each Placee, and any person acting
on behalf of the Placee, acknowledges and agrees that the Joint
Bookrunners, or any Joint Bookrunner Affiliate may, at their
absolute discretion, agree to become a Placee in respect of some or
all of the Placing Shares.
The rights and remedies of the Joint
Bookrunners and the Company under these terms and conditions are in
addition to any rights and remedies which would otherwise be
available to each of them and the exercise or partial exercise or
partial exercise of one will not prevent the exercise of
others.
Each Placee may be asked to disclose
in writing or orally to either of the Joint Bookrunners and, if so,
undertakes to provide:
(a) if he is
an individual, his nationality;
(b) if he is
a discretionary fund manager, the jurisdiction in which the funds
are managed or owned; and
(c) such
other "know your client" information as either of the Joint
Bookrunners may reasonably request (including, in order to ensure
compliance with the Regulations).
The price of shares and any income
expected from them may go down as well as up and investors may not
get back the full amount invested upon disposal of the shares. Past
performance is no guide to future performance, and persons needing
advice should consult an independent financial adviser.
The provisions of this Appendix may
be waived, varied or modified as regards specific Placees or on a
general basis by the Joint
Bookrunners.
DEFINITIONS
The following definitions apply
throughout this Announcement, unless the context requires
otherwise:
Admission
|
admission of the New Ordinary Shares
of the Company to trading on AIM becoming effective in accordance
with Rule 29 of the AIM Rules
|
AIM
|
the market of that name operated by
the London Stock Exchange
|
AIM
Rules
|
the AIM Rules for Companies and the
AIM Rules for Nominated Advisers
|
AIM
Rules for Companies
|
the rules for companies whose
securities are admitted to trading on AIM published by the London
Stock Exchange as amended from time to time
|
AIM
Rules for Nominated Advisers
|
the rules for nominated advisers to
companies whose securities are admitted to trading on AIM published
by the London Stock Exchange as amended from time to
time
|
Announcement
|
this announcement, including the
Appendix
|
AVO
|
Amplitude versus offset
|
Articles
|
the articles of association of the
Company from time to time
|
Board
|
the board of directors of the
Company from time to time
|
Bookbuilding Process
|
the accelerated bookbuild process
run by Canaccord and Zeus Capital to determine demand for
participation in the Placing by potential Placees at the Issue
Price
|
CA
2006
|
the Companies Act 2006, as
amended
|
Canaccord
|
Canaccord Genuity Limited, the
Company's nominated adviser and broker
|
Canaccord Affiliate
|
any subsidiary of Canaccord, any
branch or associated undertaking of Canaccord, any entity
controlled by Canaccord (control for these purposes meaning the
power to direct or cause the direction of the management, policies
or activities of a person, whether through the ownership of
securities, by contract or agency or otherwise) or any of their
respective directors, officers, employees, agents or
advisers
|
City Code
|
the City Code on Takeovers and
Mergers
|
CJA
|
the Criminal Justice Act
1993
|
Company or Pantheon
|
Pantheon Resources plc, incorporated
and registered in England and Wales (with registration number
05385506), whose registered office is at 6th Floor 60 Gracechurch
Street, London, United Kingdom, EC3V 0HR
|
Convertible Bond
|
the US$55 million convertible bonds
due 2026 in the capital of the Company, a summary of certain of the
key terms of which were announced on 7 December 2021
|
CREST
|
the computerised settlement system
(as defined in the CREST Regulations) operated by Euroclear which
facilitates the holding and transfer of title to shares in
uncertificated form
|
CREST Regulations
|
the Uncertificated Securities
Regulations 2001 (SI 2001 No. 2001/3755) and any modification
thereof or any regulations in substitution thereof for the time
being in force
|
Directors
|
the directors of the Company as at
the date of this Announcement
|
Euroclear
|
Euroclear UK & International
Limited, a company incorporated in England and Wales and the
operator of CREST
|
EUWA
|
the European Union (Withdrawal) Act
2018, as amended
|
Existing Ordinary Shares
|
the 960,919,660 Ordinary Shares in
issue at the date of this Announcement
|
FCA
|
the Financial Conduct Authority of
the United Kingdom
|
FPO
|
the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005
|
FSMA
|
the Financial Services and Markets
Act 2000, as amended
|
Fundraise
|
the Placing and the
Subscription
|
Group
|
the Company and its subsidiaries
from time to time
|
Issue Price
|
17 pence per New Ordinary
Share
|
Joint Bookrunners
|
Canaccord and Zeus
Capital
|
Joint Bookrunner Affiliate
|
Either a Zeus Capital Affiliate or a
Canaccord Affiliate
|
London Stock Exchange
|
London Stock Exchange plc
|
New
Ordinary Shares
|
the Placing Shares, the Subscription
Shares and the Retail Offer Shares
|
Ordinary Shares
|
ordinary shares of 1 pence each in
the capital of the Company
|
Pantheon Affiliate
|
the Company, any subsidiary of the
Company, any branch, affiliate or associated undertaking of any
such company and any of their respective directors, officers and
employees
|
Placees
|
subscribers for Placing Shares
pursuant to the Bookbuilding Process
|
Placing
|
the proposed placing to
institutional investors of new Ordinary Shares by Canaccord and
Zeus Capital on behalf of the Company pursuant to the Bookbuilding
Process
|
Placing Agreement
|
the agreement dated 25 July 2024
between the Company, Canaccord and Zeus Capital relating to the
Placing
|
Placing Shares
|
the number of new Ordinary Shares to
be issued by the Company at the Issue Price pursuant to the
Placing, with the actual number to be set out in the Placing
Results Announcement
|
Prospectus Regulation
|
(i) EU Prospectus Regulation
2017/1129 and includes any relevant implementing directive measure
in any member state; or (ii) EU Prospectus Regulation
2017/1129, as it forms part of domestic UK
law pursuant to the EUWA (as the context requires)
|
Qualified Investors
|
persons falling within the meaning
of Article 2(e) of the Prospectus Regulation
|
Regulatory Information Service
|
has the same meaning as in the AIM
Rules
|
Restricted Jurisdiction
|
each and any of the United States of
America, Australia, Canada, Japan, New Zealand, and the Republic of
South Africa
|
Securities Act
|
the US Securities Act of 1933, as
amended
|
Shareholders or member
|
holders of Existing Ordinary Shares
in the Company
|
Subscribers
|
subscribers for the Subscription
Shares
|
Subscription
|
the proposed subscription by certain
individuals and institutions of new Ordinary Shares arranged by the
Company pursuant to the Subscription Agreements
|
Subscription Agreements
|
the agreements between the Company
and the Subscribers relating to the Subscription
|
Subscription Shares
|
new Ordinary Shares to be issued by
the Company at the Issue Price pursuant to the
Subscription
|
Subsidiary and subsidiary undertaking
|
have the meanings given to them by
CA 2006
|
UK or United Kingdom
|
the United Kingdom of Great Britain
and Northern Ireland
|
UK
MAR
|
the Market Abuse Regulation (EU) No
596/2014 (as it forms part of UK domestic
law by virtue of the EUWA)
|
uncertificated or in uncertificated form
|
recorded on the relevant register of
the share or security concerned as being held in uncertificated
form in CREST and title to which, by virtue of the CREST
Regulations, may be transferred by means of CREST
|
US
or United States
|
the United States of America, its
territories and possessions, any state of the United States of
America and the district of Columbia and all other areas subject to
its jurisdiction
|
Zeus Capital
|
Zeus Capital Limited,
the Company's joint
bookrunner
|
Zeus Affiliate
|
any subsidiary of Zeus Capital, any
branch or associated undertaking of Zeus Capital, any entity
controlled by Zeus Capital (control for these purposes meaning the
power to direct or cause the direction of the management, policies
or activities of a person, whether through the ownership of
securities, by contract or agency or otherwise) or any of their
respective directors, officers, employees, agents or
advisers
|
Unless otherwise indicated, all
references in this Announcement to "GBP", "£", "pounds sterling", "pounds", "sterling", "pence" or "p" are to the lawful currency of the
United Kingdom and all references to "$", "US$", "USD" or "US dollars" are to the lawful currency
of the United States.